CTC BIO

씨티씨바이오 · 060590

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$58.1M (₩80.2B)

Overview

CTC BIO makes medicines and health products for both animals and humans, ranging from digestive enzyme treatments to film-dissolving oral doses and combination drug formulations.

Its products are used across veterinary and human healthcare, and it supplies both the domestic South Korean market and international markets. Listed on KOSDAQ, Korea's tech and small-cap board, the company carries a portfolio of hundreds of distinct products, meaning no single item dominates its revenue.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$89.7M

▼ −14.3% YoY

Operating profit · FY2025

US$4.5M

Turned profitable

Net income · FY2025

US$2.3M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$99.9M(₩137.9B)	US$104.6M(₩144.4B)	US$89.7M(₩123.8B)
Operating profit	−US$3.3M(−₩4.6B)	−US$2.9M(−₩4B)	US$4.5M(₩6.2B)
Net income	−US$11.3M(−₩15.6B)	−US$3.8M(−₩5.2B)	US$2.3M(₩3.2B)

Revenue

FY2023US$99.9M
FY2024US$104.6M
FY2025US$89.7M

Operating profit

FY2023−US$3.3M
FY2024−US$2.9M
FY2025US$4.5M

Net income

FY2023−US$11.3M
FY2024−US$3.8M
FY2025US$2.3M

Key ratios (FY2025)

ROE

4.5%

Debt/Eq

97.0%

Op. margin

5.0%

Net margin

2.6%

Rev. YoY

▼ −14.3%

Why it matters

CTC BIO holds proprietary core technologies including microbial fermentation, drug coating, and drug-delivery systems that underpin its in-house product development across both its animal and human medicine divisions.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?